Completed PHASE3 INTERVENTIONAL NCT00137410

Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee

Protocol For A Multicentre, Double Blind, Parallel Group Pilot Study To Compare Celecoxib Long Term Vs Celecoxib Short Term Therapy In Treatment And Prevention Of New Flare In Patients With Osteoarthritis Of The Knee

Sponsor: Pfizer

Conditions Osteoarthritis,Knee

Interventions Celebrex

Updated 6 times since 2017 Last updated: Jun 9, 2008 Started: Nov 30, 2002 Primary completion: Mar 31, 2006 Completion: Mar 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Osteoarthritis,Knee, this trial is completed. The trial is conducted by Pfizer and has accumulated 6 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arenzano (GE), Italy , Cagliari - Monserrato, Italy , Foggia, Italy , Genova, Italy , Jesi ( AN), Italy , Milan, Italy , Padua, Italy , Palermo, Italy , Pavia, Italy , Potenza, Italy and 4 more locations